GHRP-2 and GHRP-6 are closely related growth-hormone-releasing peptides — both act on the ghrelin receptor to trigger a GH pulse. The practical difference is in their "side activity": GHRP-6 causes a strong hunger spike, while GHRP-2 stimulates appetite less but is a potent GH releaser. Neither is approved; both are banned in sport.
At a glance
| GHRP-2 | GHRP-6 | |
|---|---|---|
| Class | GHRP (ghrelin-receptor agonist) | GHRP (ghrelin-receptor agonist) |
| Appetite effect | Milder increase | Strong increase |
| GH release | Potent | Strong |
| Cortisol / prolactin | Can increase slightly | Can increase |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
The bottom line
Bottom line: Same family, same receptor — the main distinction is appetite. GHRP-6 is notorious for strong hunger stimulation, which some seek and others avoid; GHRP-2 delivers a potent GH pulse with less of an appetite effect. Neither is an approved medicine, both can nudge cortisol/prolactin, and both are prohibited in sport.
Frequently asked questions
What's the difference between GHRP-2 and GHRP-6?
Both are GHRPs that release growth hormone via the ghrelin receptor. The key difference is appetite: GHRP-6 strongly increases hunger, while GHRP-2 does so less while remaining a potent GH releaser.
Which is more potent for GH release?
Both are potent; GHRP-2 is often described as a strong GH secretagogue with less appetite stimulation than GHRP-6. Human outcome data for either are limited.
Are they approved or legal in sport?
Neither is FDA-approved; both are sold as research chemicals and are banned at all times under the World Anti-Doping Agency code.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Pralmorelin (GHRP-2): growth hormone-releasing peptide 2. Drugs R D. 2004. Peer-reviewed study
- Okano M, Sato M, Kageyama S. Determination of pralmorelin (GHRP-2) and its metabolite in human urine by LC/ESI tandem mass spectrometry. Rapid Commun Mass Spectrom. 2010. Peer-reviewed study
- Cox HD, Hughes CM, Eichner D. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug Test Anal. 2015. Peer-reviewed study
- Yamamoto D, Ikeshita N, Matsubara T, et al. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008. Peer-reviewed study
- Laferrère B, Abraham C, Russell CD, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005. Peer-reviewed study
- Chen C, Farnworth P, Petersenn S, et al. Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells. Endocrine. 1998. Peer-reviewed study
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996. Peer-reviewed study
- Frago LM, Paneda C, Argente J, Chowen JA. GHRP-6 increases IGF-I mRNA and activates Akt in RCA-6 cells. J Neuroendocrinol. 2005. Peer-reviewed study
- Pombo M, Leal-Cerro A, Barreiro J, et al. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J Pediatr Endocrinol Metab. 1996. Peer-reviewed study
- Zhao X, Pan K, Li R, et al. Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. J Nanobiotechnology. 2025. Peer-reviewed study
- Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024. Peer-reviewed study
- Yu AP, Pei XM, Sin TK, et al. [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle. Mol Cell Endocrinol. 2015. Peer-reviewed study